Aprea Expands Cancer Trial as APR-1051 Shows Early Activity
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (NASDAQ: APRE) is expanding its Phase 1 trial of experimental cancer drug APR-1051 after reporting early signs of antitumor activity, using proceeds from a …
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity Read More